Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Operating Expenses data on record, last reported at $33.7 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 34.41% year-over-year to $33.7 million; the TTM value through Sep 2025 reached $192.1 million, down 23.1%, while the annual FY2024 figure was $258.6 million, 13.65% down from the prior year.
  • Operating Expenses reached $33.7 million in Q3 2025 per ZNTL's latest filing, down from $36.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $103.9 million in Q2 2023 and bottomed at $33.7 million in Q3 2025.
  • Average Operating Expenses over 4 years is $60.1 million, with a median of $62.7 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 63.75% in 2023, then tumbled 44.65% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $51.8 million in 2022, then skyrocketed by 31.24% to $67.9 million in 2023, then grew by 12.94% to $76.7 million in 2024, then crashed by 56.03% to $33.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $33.7 million in Q3 2025, $36.1 million in Q2 2025, and $45.6 million in Q1 2025.